🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07133984
Recruiting Observational

STICH3C Cardiac Magnetic Resonance Observational Study

NCT07133984 · tracked via the Priya Life Science China tracker
Sponsor
Weill Medical College of Cornell University
Phase
Observational
Started
2024-03-01
Last updated
2025-08-21

Condition(s) studied

Ischemic Left Ventricle Systolic DysfunctionMultivessel Coronary Artery Disease

Investigational drug(s) / intervention(s)

Cardiac Magnetic Resonance Imaging

Cardiac Magnetic Resonance Imaging: Cardiac MRI, also known as cardiac magnetic resonance imaging, is a non-invasive imaging technique that uses strong magnetic fields and radio waves to produce detailed pictures of the heart and its surrounding structures

Study summary

STICOS will test the hypothesis that residual jeopardized myocardium, late gadolinium enhancement, and non-ischemic substrate after revascularization is associated with postoperative adverse cardiovascular events such as heart failure , readmission, or death.

This study will look at whether certain heart tissue abnormalities seen on MRI scans can help predict serious health problems after heart procedures like stents or bypass surgery.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Men and women ≥ 18 years old 2. LVEF ≤ 40% (quantified by echo, single-photon emission computed tomography \[SPECT\], or CMR within 2 months of enrollment) 3. Prognostically important CAD: either multivessel CAD (triple vessel or double vessel CAD including left anterior descendant artery (LAD), significant coronary stenosis defined as ≥ 70% based on coronary angiography, fractional flow reserve (FFR) ≤ 0.80 or instantaneous wave-free ratio (iFR) ≤ 0.89) or left main disease (+/- other CAD) for which significant stenosis defined as \> 50% based on coronary angiography, intravascular ultrasound (IVUS) minimum luminal area \[MLA\] value ≤ 6.0 mm2 (\< 4.5 mm2 Asian descent), or equivalent optical coherence tomography (OCT) measurements. 4. Planned CABG or PCI within 3 months Exclusion Criteria: 1. Concomitant valve disease or other condition (e.g., LV aneurysm) requiring surgical repair or replacement 2. Contraindication to CMR (i.e. magnetically activated materials), gadolinium, regadenoson/adenosine/dipyridamole 3. Active neoplasm and/or severe end-organ dysfunction with expected life expectancy less than 5 years. \-

Primary outcome measure(s)

Trial sites (9)

FacilityCityRegionStatus
NewYork-Presbyterian Brooklyn Methodist Hospital Brooklyn New York Recruiting
New York Presbyterian - Queens Flushing New York Recruiting
Weill Cornell Medicine/NewYork Presbyterian Hospital New York New York Recruiting
MU Vienna Austria Vienna Austria Recruiting
Libin Cardiovascular Institute Calgary Alberta Recruiting
Universite Laval Quebec (CRIUCPQ) Canada Québec Canada Recruiting
Sunnybrook Health Sciences Centre Toronto Canada Recruiting
Ruijin Hospital Shanghai Jiao Tong University School of Medicine Shanghai China Recruiting
Dedinje Cardiovascular Institute Belgrade Serbia Recruiting

More Weill Medical College of Cornell University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07133984 on ClinicalTrials.gov ↗ ← All trials in China